Journal
FRONTIERS IN IMMUNOLOGY
Volume 13, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2022.1032403
Keywords
Adoptive cell therapy; chimeric antigen receptors (CAR); CAR T cells; antigen-binding domain; T cell engineering; tumor immunotherapy; solid tumors
Categories
Funding
- Paceline Cancer Research Award grant from Georgia Cancer Center, Augusta University
Ask authors/readers for more resources
Despite extensive studies to improve the efficacy of chimeric antigen receptor modified T cells (CARTs) in solid tumor therapy, the overall effectiveness remains limited. This article analyzes published trials and identifies that CARTs with moderate-affinity antigen-binding domains (ABDs) show better clinical responses and less off-target toxicity. The affinity and engaging kinetics of ABDs play a crucial role in designing effective CARTs for solid tumors.
The overall efficacy of chimeric antigen receptor modified T cells (CARTs) remain limited in solid tumors despite intensive studies that aim at targeting multiple antigens, enhancing migration, reducing tonic signaling, and improving tumor microenvironment. On the other hand, how the affinity and engaging kinetics of antigen-binding domain (ABD) affects the CART's efficacy has not been carefully investigated. In this article, we first analyzed 38 published solid tumor CART trials and correlated the response rate to their ABD affinity. Not surprisingly, majority (25 trials) of the CARTs utilized high-affinity ABDs, but generated merely 5.7% response rate. In contrast, 35% of the patients treated with the CARTs built from moderate-affinity ABDs had clinical responses. Thus, CARTs with moderate-affinity ABDs not only have less off-target toxicity, but also are more effective. We then reviewed the effects of ABD affinity on the biology and function of CARTs, providing further evidence that moderate-affinity ABDs may be better in CART development. In the end, we propose that a fast-on/fast-off (high K-on and K-off) kinetics of CART-target engagement in solid tumor allow CARTs to generate sufficient signaling to kill tumor cells without being driven to exhaustion. We believe that studying the ABD affinity and the kinetics of CART-tumor interaction may hold a key to designing effective CARTs for solid tumors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available